323 related articles for article (PubMed ID: 21216131)
41. B cell activating factor, its role in autoimmunity, and targeting in autoimmune diseases.
Krivosikova M; Dallos T; Maslinski W; Buc M
Bratisl Lek Listy; 2009; 110(3):137-45. PubMed ID: 19507632
[TBL] [Abstract][Full Text] [Related]
42. B cells flying solo.
Groom J; Mackay F
Immunol Cell Biol; 2008 Jan; 86(1):40-6. PubMed ID: 18172443
[TBL] [Abstract][Full Text] [Related]
43. BAFF and MyD88 signals promote a lupuslike disease independent of T cells.
Groom JR; Fletcher CA; Walters SN; Grey ST; Watt SV; Sweet MJ; Smyth MJ; Mackay CR; Mackay F
J Exp Med; 2007 Aug; 204(8):1959-71. PubMed ID: 17664289
[TBL] [Abstract][Full Text] [Related]
44. Subset size, activation threshold and distribution of autoreactive MZ and FO B cells do not differ in a sex-specific manner in the NZB/W F1 murine lupus model: an experimental mouse study.
Enghard P; Grussie E; Rieder C; Burmester GR; Riemekasten G
Lupus; 2011 Oct; 20(12):1240-9. PubMed ID: 21844114
[TBL] [Abstract][Full Text] [Related]
45. KR33426, [2-(2,5-dichlorophenyl)-5-methyloxazol-4yl]carbonylguanidine, is a novel compound to be effective on mouse systemic lupus erythematosus.
Lee GH; Oh JM; Kim HS; Yoon WK; Yi KY; Yang Y; Han SH; Lee S; Moon EY
Eur J Pharmacol; 2011 Oct; 668(3):459-66. PubMed ID: 21827747
[TBL] [Abstract][Full Text] [Related]
46. CD22 x Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity.
Jellusova J; Wellmann U; Amann K; Winkler TH; Nitschke L
J Immunol; 2010 Apr; 184(7):3618-27. PubMed ID: 20200274
[TBL] [Abstract][Full Text] [Related]
47. An increase in B cell apoptosis by interfering BAFF-BAFF-R interaction with small synthetic molecules.
Moon EY; Yi KY; Lee S
Int Immunopharmacol; 2011 Oct; 11(10):1523-33. PubMed ID: 21620999
[TBL] [Abstract][Full Text] [Related]
48. BAFF suppresses IL-15 expression in B cells.
Ma N; Xing C; Xiao H; He Y; Han G; Chen G; Hou C; Marrero B; Wang Y; Zhang S; Shen B; Li Y; Wang R
J Immunol; 2014 May; 192(9):4192-201. PubMed ID: 24670802
[TBL] [Abstract][Full Text] [Related]
49. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
Vincent FB; Morand EF; Mackay F
Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
[TBL] [Abstract][Full Text] [Related]
50. Regulation of the B cell receptor repertoire and self-reactivity by BAFF.
Ota M; Duong BH; Torkamani A; Doyle CM; Gavin AL; Ota T; Nemazee D
J Immunol; 2010 Oct; 185(7):4128-36. PubMed ID: 20817867
[TBL] [Abstract][Full Text] [Related]
51. BAFF augments certain Th1-associated inflammatory responses.
Sutherland AP; Ng LG; Fletcher CA; Shum B; Newton RA; Grey ST; Rolph MS; Mackay F; Mackay CR
J Immunol; 2005 May; 174(9):5537-44. PubMed ID: 15843552
[TBL] [Abstract][Full Text] [Related]
52. The complexity of the BAFF TNF-family members: implications for autoimmunity.
Lahiri A; Pochard P; Le Pottier L; Tobón GJ; Bendaoud B; Youinou P; Pers JO
J Autoimmun; 2012 Sep; 39(3):189-98. PubMed ID: 22749832
[TBL] [Abstract][Full Text] [Related]
53. Neutrophils contribute to excess serum BAFF levels and promote CD4+ T cell and B cell responses in lupus-prone mice.
Coquery CM; Wade NS; Loo WM; Kinchen JM; Cox KM; Jiang C; Tung KS; Erickson LD
PLoS One; 2014; 9(7):e102284. PubMed ID: 25010693
[TBL] [Abstract][Full Text] [Related]
54. Prevention of murine antiphospholipid syndrome by BAFF blockade.
Kahn P; Ramanujam M; Bethunaickan R; Huang W; Tao H; Madaio MP; Factor SM; Davidson A
Arthritis Rheum; 2008 Sep; 58(9):2824-34. PubMed ID: 18759321
[TBL] [Abstract][Full Text] [Related]
55. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice.
Ramanujam M; Bethunaickan R; Huang W; Tao H; Madaio MP; Davidson A
Arthritis Rheum; 2010 May; 62(5):1457-68. PubMed ID: 20131293
[TBL] [Abstract][Full Text] [Related]
56. BAFF overexpression promotes anti-dsDNA B-cell maturation and antibody secretion.
Thorn M; Lewis RH; Mumbey-Wafula A; Kantrowitz S; Spatz LA
Cell Immunol; 2010; 261(1):9-22. PubMed ID: 19914608
[TBL] [Abstract][Full Text] [Related]
57. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF.
Jacob CO; Pricop L; Putterman C; Koss MN; Liu Y; Kollaros M; Bixler SA; Ambrose CM; Scott ML; Stohl W
J Immunol; 2006 Aug; 177(4):2671-80. PubMed ID: 16888029
[TBL] [Abstract][Full Text] [Related]
58. Pathogenesis of lupus-like nephritis through autoimmune antibody produced by CD180-negative B lymphocytes in NZBWF1 mouse.
Fujita K; Akasaka Y; Kuwabara T; Wang B; Tanaka K; Kamata I; Yokoo T; Kinoshita T; Iuchi A; Akishima-Fukasawa Y; Ishikawa Y; Kondo M; Ishii T
Immunol Lett; 2012 May; 144(1-2):1-6. PubMed ID: 22387632
[TBL] [Abstract][Full Text] [Related]
59. Intrinsic molecular factors cause aberrant expansion of the splenic marginal zone B cell population in nonobese diabetic mice.
Stolp J; Mariño E; Batten M; Sierro F; Cox SL; Grey ST; Silveira PA
J Immunol; 2013 Jul; 191(1):97-109. PubMed ID: 23740954
[TBL] [Abstract][Full Text] [Related]
60. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.
Mackay F; Woodcock SA; Lawton P; Ambrose C; Baetscher M; Schneider P; Tschopp J; Browning JL
J Exp Med; 1999 Dec; 190(11):1697-710. PubMed ID: 10587360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
